SCHEMBL6134005

SCHEMBL6134005

C[C@H](OCc1ccccc1)[C@@H](CCOc1cccc2ccccc12)n1cnc(C(N)=O)c1

nearest known ligand 0.54

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ADA P00813 11/20 0.54
KMT2A Q03164 1/20 0.39
XIAP P98170 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
MCL1 Q07820 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5672386 0.87 ADA (0.53) ADAKMT2AMRGPRX4
SCHEMBL6169583 0.86 ADA (0.73) ADAKMT2A
SCHEMBL6169932 0.86 ADA (0.73) ADAKMT2A
SCHEMBL6173047 0.86 ADA (0.73) ADAKMT2A
SCHEMBL6133389 0.86 ADA (0.71) ADAMCL1
SCHEMBL6170051 0.85 ADA (0.65) ADAKMT2A
SCHEMBL6133927 0.85 ADA (0.75) ADA
SCHEMBL6173054 0.83 ADA (0.52) ADA
SCHEMBL6169449 0.83 ADA (0.60) ADA
SCHEMBL5671892 0.83 ADA (0.55) ADA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6908940-B2 Imidazole compounds and their use as adenosine deaminase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-21 US claimed
US-20040097571-A1 Imidazole compounds and their use as adenosine deaminase inhibitors ASTELLAS PHARMA INC. (JP) 2004-05-20 US claimed
US-6908940-B2 Imidazole compounds and their use as adenosine deaminase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-21 US disclosed
US-20040097571-A1 Imidazole compounds and their use as adenosine deaminase inhibitors ASTELLAS PHARMA INC. (JP) 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097571-A1 Imidazole compounds and their use as adenosine deaminase inhibitors ADA, AMPD2, AMPD1 ADA 1/4885KMT2A 1022/4885XIAP 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.